Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence

Kidney International Reports(2025)10.1016/j.ekir.2025.10.018Source: DataRank Database

Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence is a research paper published in Kidney International Reports (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.79)OA: goldTopics (12)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Masroor Habeeb,Hong Chen ORCID,Zainab Alhamal,Omar Mamlouk ORCID,Heather Lin ORCID

Live enrichment

PubMed:41541786 PMC:PMC12799554 OpenAlex:https://openalex.org/W4415716795

University of Texas MD Anderson Cancer Center

NIH

FWCI

1.79

Citation Percentile

0.9%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://www.kireports.org/article/S2468-0249(25)00662-X/pdf

publisherhttps://www.kireports.org/article/S2468-0249(25)00662-X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S246802492500662X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S246802492500662X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ekir.2025.10.018

Fields of Study

Cancer Immunotherapy and Biomarkersvaccines and immunoinformatics approachesComplement system in diseases

Keywords

InfliximabImmune systemAntibodyNephritisImmune checkpointTumor necrosis factor alphaAcute Interstitial NephritisImmune Checkpoint InhibitorInfliximab Tnf

Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence

FAIR Checklist

Authors (12)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)